MPG.eBooks - Description: CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.)

Read Now

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ixekizumab be reimbursed for patients with moderate to severe plaque psoriasis

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, October 25, 2016
Series:	CADTH common drug review
Subjects:	Antibodies, Monoclonal, Humanized / Economics Canada Cost-benefit Analysis Insurance, Pharmaceutical Services / Economics Insurance, Health, Reimbursement / Economics Drug Costs Psoriasis / Drug Therapy
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK533714
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that ixekizumab be reimbursed for patients with moderate to severe plaque psoriasis
Physical Description:	1 PDF file (7 pages)